BDBM461424 US10774070, Compound Vandetanib::US10807986, Example Vandetanib

SMILES CN1CCC(COc2cc3ncnc(Cc4ccc(Br)cc4F)c3cc2C)CC1

InChI Key InChIKey=XCZFQNKLJUWULA-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 461424   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 1.20nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 9.20nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 607nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 902nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 4.33E+3nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Blueprint Medicines

US Patent
LigandPNGBDBM461424(US10774070, Compound Vandetanib | US10807986, Exam...)
Affinity DataIC50: 4.75E+3nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
US Patent